医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Abcam Establishes New Direct Service for Australia and New Zealand

2014年08月12日 PM05:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England

Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has established a direct service to Australia and New Zealand. The move signifies the importance of this region and Abcam’s focus on providing the best products and services to accelerate the pace of researchers’ scientific discoveries.

The new service enables customers in Australia and New Zealand to order their research tools directly from Abcam rather than through a distributor. These customers will also benefit from direct technical support, and delivery times reduced by up to 50% from order to delivery.

Philippe Cotrel, Commercial Director, Abcam, said: “I’m delighted that we can offer an enhanced service to our customers in Australia and New Zealand. A direct service will enable us to develop closer relationships with our customers, and ensure we are fully meeting their research needs.”

Abcam’s experienced technical and customer support teams and in-house manufacturing facilities provide researchers worldwide with high-performance products that they can trust, such as RabMAb® primaries.

To find out more, please visit www.abcam.com

About Abcam

Abcam plc is a global leader in the supply of innovative protein research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

CONTACT

Abcam
Francesca Axe
T: +44 (0) 1223 696000
or
Media
enquiries

Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T:
+44 (0) 7787 502 947

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists